{"id":61166,"date":"2025-04-28T16:06:40","date_gmt":"2025-04-28T14:06:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/"},"modified":"2025-04-28T16:06:40","modified_gmt":"2025-04-28T14:06:40","slug":"epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/","title":{"rendered":"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>EpiTAC platform can also combine with drug payload delivery to deepen anti-tumor activity and reach broader tumor indications, supporting first-in-class potential<\/i>\n<\/p>\n<p>SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.epibiologics.com%2F&amp;esheet=54244808&amp;newsitemid=20250428191743&amp;lan=en-US&amp;anchor=EpiBiologics&amp;index=1&amp;md5=b28233d6b180c200ee0892e5db2da484\" rel=\"nofollow\" shape=\"rect\">EpiBiologics<\/a>, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class therapy for a range of cancers driven by mutated, amplified, or overexpressed c-Met signaling. The data, which were presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting, show that c-Met degrading EpiTACs demonstrate strong anti-tumor activity<i> in vivo <\/i>and as ADCs, combining c-Met degradation with payload-dependent cell killing to broaden the clinical opportunity into tumors that are not solely dependent on c-Met signaling for survival.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/5\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/22\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/5\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/21\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\"><\/a><\/p>\n<p>\nc-Met is a receptor tyrosine kinase that acts as both a pathogenic driver and disease marker in multiple tumor types, including non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer and renal cancer. While tyrosine kinase inhibitors are approved for tumors with c-Met mutations, targeted therapies for c-Met-amplified or -overexpressed tumors are lacking, hampered by the need for high levels of c-Met expression and variable dependency on c-Met for tumor cell survival and proliferation.\n<\/p>\n<p>\nKey highlights of EpiBiologics\u2019 data include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nc-Met EpiTACs degraded oncogenic mutant and wildtype forms of c-Met on tumor cells and demonstrated sustained tumor growth suppression in a patient-derived mouse model of NSCLC.\n<\/li>\n<li>\nDegradation of c-Met resulted in deep anti-tumor activity, driven by the ability of EpiTACs to remove the oncogenic protein and associated scaffolding.\n<\/li>\n<li>\nCombining targeted protein degradation of c-Met with a cytotoxic ADC payload suppressed tumor growth in c-Met-mutant, c-Met-amplified, and c-Met-overexpressed tumors, potentially broadening the clinical opportunity into tumors that have low c-Met expression and are not solely dependent on c-Met signaling for survival.\n<\/li>\n<\/ul>\n<p>\n\u201cWe\u2019re pleased to share data from our c-Met EpiTAC program, confirming our platform\u2019s ability to drive deep and durable degradation with therapeutically relevant impact. These data underscore how we can flexibly tune EpiTACs to have specific characteristics that solve the limitations of current clinical therapies,\u201d said Shyra Gardai, Ph.D., Chief Scientific Officer of EpiBiologics. \u201cAdditionally, this dataset showed that there is exciting potential, in certain therapeutic settings, for augmenting our bispecific antibodies with a cytotoxic payload to drive even broader patient benefit.\u201d\n<\/p>\n<p>\n\u201cc-Met represents one of several important targets in our pipeline of EpiTAC bispecific antibodies,\u201d said Ann Lee-Karlon, Ph.D., Chief Executive Officer of EpiBiologics. \u201cAs our lead tissue-selective EGFR degrader moves rapidly toward the clinic, we are also advancing EpiTACs for membrane, soluble, and GPCR targets. We have demonstrated strong single-agent activity and can successfully combine with current standards-of-care, paving the way for future therapies.\u201d\n<\/p>\n<p>\nThe poster, entitled &#8220;Discovery of c-MET degrading bispecific antibodies (EpiTACs) for NSCLC and other c-MET driven tumors,\u201d will be available on the company\u2019s website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.epibiologics.com%2Four-science&amp;esheet=54244808&amp;newsitemid=20250428191743&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=91c30d218d3deb09e4cf3ef5178d61f7\" rel=\"nofollow\" shape=\"rect\">here<\/a> when presentation concludes.\n<\/p>\n<p>\n<b>About EpiBiologics<\/b>\n<\/p>\n<p>\nEpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets membrane and extracellular proteins. EpiBiologics was founded on pioneering work from scientific founder Dr. Jim Wells of the University of California, San Francisco (UCSF). The Company\u2019s proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Preclinical anti-tumor data support the innovative EpiTAC approach to extracellular protein degradation as the company advances toward the clinic. Headquartered in the San Francisco Bay Area, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology and immunology. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fepibiologics.com&amp;esheet=54244808&amp;newsitemid=20250428191743&amp;lan=en-US&amp;anchor=epibiologics.com&amp;index=3&amp;md5=0dac7b8e32f8f735f27fd04e83351ccb\" rel=\"nofollow\" shape=\"rect\">epibiologics.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fepibiologics-inc%2F&amp;esheet=54244808&amp;newsitemid=20250428191743&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=2631619765da4028a88860b82ea3f5ce\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media<\/b><br \/>Lisa Raffensperger<br \/>\n<br \/>Ten Bridge Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;lt&#x6f;&#x3a;&#108;&#105;s&#x61;&#x40;&#116;&#101;n&#x62;&#x72;&#x69;&#100;ge&#x63;&#x6f;&#109;&#109;u&#x6e;&#x69;&#99;&#97;t&#x69;&#x6f;&#110;&#115;&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x6c;&#105;&#115;a&#x40;&#x74;&#101;n&#x62;&#x72;&#105;dg&#x65;&#99;&#111;m&#x6d;&#x75;&#110;i&#x63;&#x61;&#116;&#105;o&#x6e;&#x73;&#46;c&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>EpiTAC platform can also combine with drug payload delivery to deepen anti-tumor activity and reach broader tumor indications, supporting first-in-class potential SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class therapy for a range of cancers &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61166","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EpiTAC platform can also combine with drug payload delivery to deepen anti-tumor activity and reach broader tumor indications, supporting first-in-class potential SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class therapy for a range of cancers ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T14:06:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/22\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody\",\"datePublished\":\"2025-04-28T14:06:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/\"},\"wordCount\":616,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250428191743\\\/en\\\/2451104\\\/22\\\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/\",\"name\":\"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250428191743\\\/en\\\/2451104\\\/22\\\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\",\"datePublished\":\"2025-04-28T14:06:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250428191743\\\/en\\\/2451104\\\/22\\\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250428191743\\\/en\\\/2451104\\\/22\\\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/","og_locale":"en_US","og_type":"article","og_title":"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody - Pharma Trend","og_description":"EpiTAC platform can also combine with drug payload delivery to deepen anti-tumor activity and reach broader tumor indications, supporting first-in-class potential SAN MATEO, Calif.&#8211;(BUSINESS WIRE)&#8211;EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class therapy for a range of cancers ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/","og_site_name":"Pharma Trend","article_published_time":"2025-04-28T14:06:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/22\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody","datePublished":"2025-04-28T14:06:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/"},"wordCount":616,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/22\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/","url":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/","name":"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/22\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg","datePublished":"2025-04-28T14:06:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/22\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250428191743\/en\/2451104\/22\/EpiBiologics-Website-Line-Backgorund-081322-v01-FullColor-Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/epibiologics-presents-first-data-on-c-met-degrading-bispecific-antibody\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61166"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61166\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}